System
• JBAIDS provides biological agent identification and diagnostic capability for fixed-site, mobile (shelter, man portable, and trailer), and shipboard applications.
• The Services intend the JBAIDS to be a reusable, portable, biological agent identification and diagnostic system capable of identifying multiple biological warfare agents (BWAs) simultaneously.
• JBAIDS provides enhanced capabilities to the warfighter to identify conventional infectious organisms that occur naturally in the environment and BWAs.
• JBAIDS is intended to satisfy a need to rapidly identify these BWAs in environmental samples and in clinical samples after Food and Drug Administration certification.
• It consists of an analytical device, sample preparation kits, reagent kits, laptop computer, and other support equipment weighing up to 1,500 pounds and occupying up to 227 cubic feet.
• JBAIDS is intended to be employed in units such as:
- Biological Defense will make a full-rate production decision for shipboard JBAIDS in 1QFY08.
Assessment
• JBAIDS is effective in identifying BWAs in a timely manner (3-4 hours versus 28-48 hours from traditional culturing methods) and aids in improved situational awareness, isolation of personnel, and reduced exposure to the agent. • JBAIDS is operationally suitable. The JPM is making hardware and software changes to address reliability, availability, and maintainability issues remaining from the August 2007 reliability demonstration. The failure of the JBAIDS during FOT&E Navy shipboard phase prevented mission accomplishment, yet testing continued using a spare JBAIDS. Only one JBAIDS is authorized in Air Force, Marine Corps, and Navy medical units, and most Army units.
• The inclusion of extraction and inhibition controls provides
greater confidence on the part of operators and reduces false positives and false negative results. The JBAIDS analytical report sent to the laboratory physician did not indicate when the JBAIDS operator applied inhibition controls when preparing samples. Inclusion of this information would improve physician interpretation of the analytical report.
• JBAIDS software can be improved to translate the measured crossing threshold data into estimates of concentration for each BWA against different media (agent/matrix) combinations.
• The revised sample preparation protocols are effective.
One of the protocols reduces the footprint and volume of sample required but processing time increases. Additional operator training may improve techniques to limit sample contamination.
Recommendations
• Status of Previous Recommendations. All earlier DOT&E recommendations have been resolved. • FY07 Recommendations.
1. The Services should reassess quantities of JBAIDS in units to provide redundant capability. 2. The product manager should modify the JBAIDS analytical report to indicate use of inhibition controls and associated results. 3. The product manager should refine the algorithm that translates the measured crossing threshold data into estimates of concentration for the different BWA/matrix combinations.
